Recent findings on epigenetic gene abnormalities involved in uterine cancer (Review)
- Authors:
- Megumi Yanokura
- Kouji Banno
- Yusuke Kobayashi
- Hiroyuki Nomura
- Shigenori Hayashi
- Eiichiro Tominaga
- Daisuke Aoki
-
Affiliations: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo 160‑8582, Japan - Published online on: September 20, 2017 https://doi.org/10.3892/mco.2017.1428
- Pages: 733-737
This article is mentioned in:
Abstract
|
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.1Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). Lyon, France: International Agency for Research on Cancer; 2014 http://globocan.iarc.frAccessed. August 10–2016 | |
|
Bhat S, Kabekkodu SP, Noronha A and Satyamoorthy K: Biological implications and therapeutic significance of DNA methylation regulated genes in cervical cancer. Biochimie. 121:298–311. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Banzai C, Nishino K, Quan J, Yoshihara K, Sekine M, Yahata T and Tanaka K: Gynecological Cancer Registry of Niigata: Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. Int J Clin Oncol. 19:127–132. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu SS, Leung RC, Chan KY, Chiu PM, Cheung AN, Tam KF, Ng TY, Wong LC and Ngan HY: p73 expression is associated with the cellular radiosensitivity in cervical cancer after radiotherapy. Clin Cancer Res. 10:3309–3316. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Roz L, Gramegna M, Ishii H, Croce CM and Sozzi G: Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines. Proc Natl Acad Sci USA. 99:3615–3320. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Snellenberg S, Cillessen SA, Van Criekinge W, Bosch L, Meijer CJ, Snijders PJ and Steenbergen RD: Methylation-mediated repression of PRDM14 contributes to apoptosis evasion in HPV-positive cancers. Carcinogenesis. 35:2611–2618. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu Q, Shi H, Suo Z and Nesland JM: 5′-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol. 27:417–422. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Kitkumthorn N, Yanatatsanajit P, Kiatpongsan S, Phokaew C, Triratanachat S, Trivijitsilp P, Termrungruanglert W, Tresukosol D, Niruthisard S and Mutirangura A: Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. BMC Cancer. 6:552006. View Article : Google Scholar : PubMed/NCBI | |
|
Chujan S, Kitkumthorn N, Siriangkul S and Mutirangura A: CCNA1 promoter methylation: A potential marker for grading Papanicolaou smear cervical squamous intraepithelial lesions. Asian Pac J Cancer Prev. 15:7971–7975. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kabekkodu SP, Bhat S, Radhakrishnan R, Aithal A, Mascarenhas R, Pandey D, Rai L, Kushtagi P, Mundyat GP and Satyamoorthy K: DNA promoter methylation-dependent transcription of the double C2-like domain β (DOC2B) gene regulates tumor growth in human cervical cancer. J Biol Chem. 289:10637–10649. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Aoki K and Taketo MM: Adenomatous polyposis coli (APC): A multi-functional tumor suppressor gene. J Cell Sci. 120:3327–3335. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC and Yu MH: Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol. 135:1665–1674. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Narayan G, Arias-Pulido H, Nandula SV, Basso K, Sugirtharaj DD, Vargas H, Mansukhani M, Villella J, Meyer L, Schneider A, et al: Promoter hypermethylation of FANCF: Disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res. 64:2994–2997. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Henken FE, Wilting SM, Overmeer RM, van Rietschoten JG, Nygren AO, Errami A, Schouten JP, Meijer CJ, Snijders PJ and Steenbergen RD: Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer. 97:1457–1464. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res. 7:584–589. 2001.PubMed/NCBI | |
|
Bai LX, Wang JT, Ding L, Jiang SW, Kang HJ, Gao CF, Chen X, Chen C and Zhou Q: Folate deficiency and FHIT hypermethylation and HPV 16 infection promote cervical cancerization. Asian Pac J Cancer Prev. 15:9313–9317. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ivanova T, Petrenko A, Gritsko T, Vinokourova S, Eshilev E, Kobzeva V, Kisseljov F and Kisseljova N: Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer. BMC Cancer. 2:42002. View Article : Google Scholar : PubMed/NCBI | |
|
De Strooper LM, van Zummeren M, Steenbergen RD, Bleeker MC, Hesselink AT, Wisman GB, Snijders PJ, Heideman DA and Meijer CJ: CADM1, MAL and miR124-2 methylation analysis in cervical scrapes to detect cervical and endometrial cancer. J Clin Pathol. 67:1067–1071. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kim JH, Choi YD, Lee JS, Lee JH, Nam JH and Choi C: Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol. 116:99–104. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Yadav SS, Prasad SB, Das M, Kumari S, Pandey LK, Singh S, Pradhan S and Narayan G: Epigenetic silencing of CXCR4 promotes loss of cell adhesion in cervical cancer. Biomed Res Int. 2014:5814032014. View Article : Google Scholar : PubMed/NCBI | |
|
Overmeer RM, Henken FE, Snijders PJ, Claassen-Kramer D, Berkhof J, Helmerhorst TJ, Heideman DA, Wilting SM, Murakami Y, Ito A, et al: Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. J Pathol. 215:388–397. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Bischoff J, Ignatov A, Semczuk A, Schwarzenau C, Ignatov T, Krebs T, Küster D, Przadka-Rabaniuk D, Roessner A, Costa SD and Schneider-Stock R: hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases. Clin Exp Metastasis. 29:889–900. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Guida M, Sanguedolce F, Bufo P, Di Spiezio Sardo A, Bifulco G, Nappi C and Pannone G: Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol. 30:267–270. 2009.PubMed/NCBI | |
|
Pallarés J, Velasco A, Eritja N, Santacana M, Dolcet X, Cuatrecasas M, Palomar-Asenjo V, Catasús L, Prat J and Matias-Guiu X: Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma. Mod Pathol. 21:691–699. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Banno K, Yanokura M, Susumu N, Kawaguchi M, Hirao N, Hirasawa A, Tsukazaki K and Aoki D: Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep. 16:1189–1196. 2006.PubMed/NCBI | |
|
Jo H, Kim JW, Kang GH, Park NH, Song YS, Kang SB and Lee HP: Association of promoter hypermethylation of the RASSF1A gene with prognostic parameters in endometrial cancer. Oncol Res. 16:205–209. 2006.PubMed/NCBI | |
|
Lee KE: Immunohistochemical assessment of O(6)-methylguanine-DNA methyltransferase (MGMT) and Its relationship with p53 expression in endometrial cancers. J Cancer Prev. 18:351–354. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ignatov A, Bischoff J, Ignatov T, Schwarzenau C, Krebs T, Kuester D, Costa SD, Roessner A, Semczuk A and Schneider-Stock R: APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci. 101:321–327. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Suehiro Y, Okada T, Okada T, Anno K, Okayama N, Ueno K, Hiura M, Nakamura M, Kondo T, Oga A, et al: Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin Cancer Res. 14:3354–3361. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Fiolka R, Zubor P, Janusicova V, Visnovsky J, Mendelova A, Kajo K, Lasabova Z, Plank L and Danko J: Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer. Oncol Rep. 30:2878–2886. 2013.PubMed/NCBI | |
|
Park JH, Lee BI, Song ES, Whang SO, Lee WY and Cho SJ: Hypermethylation of E-cadherin in endometrial carcinoma. J Gynecol Oncol. 19:241–245. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Saito T, Nishimura M, Yamasaki H and Kudo R: Hypermethylation in promoter region of E-cadherin gene is associated with tumor dedifferention and myometrial invasion in endometrial carcinoma. Cancer. 97:1002–1009. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yang HJ, Liu VW, Wang Y, Tsang PC and Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer. 6:2122006. View Article : Google Scholar : PubMed/NCBI | |
|
Kang S, Lee JM, Jeon ES, Lee S, Kim H, Kim HS, Seo SS, Park SY, Sidransky D and Dong SM: RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. Int J Cancer. 119:1316–1321. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Vega F, Gotea V, Petrykowska HM, Margolin G, Krivak TC, DeLoia JA, Bell DW and Elnitski L: Recurrent patterns of DNA methylation in the ZNF154, CASP8 and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. Epigenetics. 8:1355–1372. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC and Cheung AN: Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn. 7:8–16. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M and Palacios J: Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res. 67:1927–1934. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wong OG, Huo Z, Siu MK, Zhang H, Jiang L, Wong ES and Cheung AN: Hypermethylation of SOX2 promoter in endometrial carcinogenesis. Obstet Gynecol Int. 2010:pii:6825042010. View Article : Google Scholar | |
|
Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N and Aoki D: Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer (Review). Oncol Rep. 22:967–972. 2009.PubMed/NCBI | |
|
Zhang QY, Yi DQ, Zhou L, Zhang DH and Zhou TM: Status and significance of CpG island methylator phenotype in endometrial cancer. Gynecol Obstet Invest. 72:183–191. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Semczuk A, Boltze C, Marzec B, Szczygielska A, Roessner A and Schneider-Stock R: p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol. 129:589–596. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki M, Oh BR, Dharia A, Fujimoto S and Dahiya R: Inactivation of the human androgen receptor gene is associated with CpG hypermethylation in uterine endometrial cancer. Mol Carcinog. 29:59–66. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Sasaki M, Dharia A, Oh BR, Tanaka Y, Fujimoto S and Dahiya R: Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res. 61:97–102. 2001.PubMed/NCBI | |
|
Li R, Saito T, Tanaka R, Satohisa S, Adachi K, Horie M, Akashi Y and Kudo R: Hypermethylation in promoter region of retinoic acid receptor-beta gene and immunohistochemical findings on retinoic acid receptors in carcinogenesis of endometrium. Cancer Lett. 219:33–40. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Dong R, Pu H, Wang Y, Yu J, Lian K and Mao C: TESTIN was commonly hypermethylated and involved in the epithelial-mesenchymal transition of endometrial cancer. APMIS. 123:394–400. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chmelarova M, Kos S, Dvorakova E, Spacek J, Laco J, Ruszova E, Hrochova K and Palicka V: Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium. Clin Chem Lab Med. 52:1229–1234. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Catasus L, Pons C, Muñoz J, Espinosa I and Prat J: Promoter hypermethylation contributes to TIMP3 down-regulation in high stage endometrioid endometrial carcinomas. Histopathology. 62:632–641. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, et al: Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3. Clin Epigenetics. 8:292016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang LY, Han CS, Li PL and Zhang XC: 5-Hydroxyme-thylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. Jpn J Clin Oncol. 46:427–434. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Iyer LM, Tahiliani M, Rao A and Aravind L: Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 8:1698–1710. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sood S and Srinivasan R: Alterations in gene promoter methylation and transcript expression induced by cisplatin in comparison to 5-azacytidine in HeLa and SiHa cervical cancer cell lines. Mol Cell Biochem. 404:181–191. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen CC, Lee KD, Pai MY, Chu PY, Hsu CC, Chiu CC, Chen LT, Chang JY, Hsiao SH and Leu YW: Changes in DNA methylation are associated with the development of drug resistance in cervical cancer cells. Cancer Cell Int. 15:982015. View Article : Google Scholar : PubMed/NCBI | |
|
Narayan G, Xie D, Ishdorj G, Scotto L, Mansukhani M, Pothuri B, Wright JD, Kaufmann AM, Schneider A, Arias-Pulido H and Murty VV: Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to Apo2L/trail-Cisplatin combination therapy in cervical cancer. Genes Chromosomes Cancer. 55:177–189. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Jascur T and Boland CR: Structure and function of the components of the human DNA mismatch repair system. Int J Cancer. 119:2030–2035. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Eto T, Zhao Y, Maruyama A, Miyashita K, Yasui A, Nakao S, Taguchi K, Shimokawa M, Oda S and Saito T: Modal variety of microsatellite instability in human endometrial carcinomas. J Cancer Res Clin Oncol. 142:353–363. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Bilbao C, Lara PC, Ramírez R, Henríquez-Hernández LA, Rodríguez G, Falcón O, León L, Perucho M, Díaz-Chico BN and Díaz-Chico JC: Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. Int J Radiat Oncol Biol Phys. 76:9–13. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I, La Jeunesse J, Nakagawa H, Westman JA, et al: Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 66:7810–7817. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Devor EJ, Schickling BM, Reyes HD, Warrier A, Lindsay B, Goodheart MJ, Santillan DA and Leslie KK: Cullin-5, a ubiquitin ligase scaffold protein, is significantly underexpressed in endometrial adenocarcinomas and is a target of miR-182. Oncol Rep. 35:2461–2465. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J and Hu Y: microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncol Reports. 27:807–812. 2012. | |
|
Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Wei Z, Kamath S, Chen DT, Dressman H and Lancaster JM: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol. 110:206–215. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lee H, Park CS, Deftereos G, Morihara J, Stern JE, Hawes SE, Swisher E, Kiviat NB and Feng Q: MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol. 10:1742012. View Article : Google Scholar : PubMed/NCBI | |
|
Li S, Yang C, Zhai L, Zhang W, Yu J, Gu F, Lang R, Fan Y, Gong M, Zhang X and Fu L: Deep sequencing reveals small RNA characterization of invasive micropapillary carcinomas of the breast. Breast Cancer Res Treat. 136:77–87. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al: Relation between microRNA expression and progression and prognosis of gastric cancer: A microRNA expression analysis. Lancet Oncol. 11:136–146. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Duenas-Gonzalez A, Medina-Franco JL, Chavez-Blanco A, Dominguez-Gomez G and Fernández-de Gortari E: Developmental DNA methyltransferase inhibitors in the treatment of gynecologic cancers. Expert Opin Pharmacother. 17:323–338. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Song Y and Zhang C: Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol. 63:605–613. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D and Inazawa J: miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 71:6450–6462. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao X, Zhu D, Lu C, Yan D, Li L and Chen Z: MicroRNA-126 inhibits the migration and invasion of endometrial cancer cells by targeting insulin receptor substrate 1. Oncol Lett. 11:1207–1212. 2016.PubMed/NCBI | |
|
Ren J, Zhang J, Cai H, Li Y, Zhang Y, Zhang X, Zhao D, Li Z, Ma H, Wang J, et al: HDAC as a therapeutic target for treatment of endometrial cancers. Curr Pharm Des. 20:1847–1856. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yi TZ, Li J, Han X, Guo J, Qu Q, Guo L, Sun HD and Tan WH: DNMT inhibitors and HDAC inhibitors regulate E-cadherin and bcl-2 expression in endometrial carcinoma in vitro and in vivo. Chemotherapy. 58:19–29. 2012. View Article : Google Scholar : PubMed/NCBI |
